UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~May~~Date 25of Report (Date of earliest event reported): June 3, 2022

OCEAN BIO-CHEM, INC.

(Exact name of registrant as specified in charter)

Florida		0-11102		59-1564329
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

4041 S.W. 47 Avenue, Fort Lauderdale, Florida		33314
(Address of principal executive offices)		(Zip Code)

(954) 587-6280

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)				Name of each exchange on which registered
Title of Each Class	Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value	OBCI	~~OBCI~~	The NASDAQ Stock Market	~~The NASDAQ Stock Market~~

~~Item~~ Indicate 8by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.01405 ~~Other~~of ~~Events~~this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

~~On May~~Emerging ~~25,~~Growth ~~2022, Ocean Bio-Chem, Inc. (the “~~Company”) ~~the Board of Directors voted and approved the quarterly regular dividend of $0.04 per/share.~~☐

~~The~~If ~~information~~an ~~furnished~~emerging ~~pursuant~~growth ~~to Item 8.01 of this Current Report~~company, ~~including~~ ~~the~~indicate ~~exhibits~~by ~~furnished~~check ~~herewith,~~mark ~~shall~~if ~~not be deemed “filed” for purposes of Section 18 of~~ the ~~Securities Exchange~~registrant ~~Act~~has ofelected ~~1934,~~not ~~as amended, or otherwise subject~~ to ~~the~~use ~~liabilities of that section, nor shall it be incorporated by reference into future filings by~~ the ~~Company~~extended ~~under~~transition ~~the~~period ~~Securities~~for ~~Act~~complying ofwith ~~1933,~~any asnew ~~amended,~~ or ~~under~~revised ~~the~~financial ~~Securities~~accounting ~~Exchange~~standards ~~Act~~provided ~~of 1934, as amended, unless~~pursuant ~~the Company expressly sets forth in such future filing that such information is~~ to beSection ~~considered~~13(a) ~~“filed”~~of orthe ~~incorporated~~Exchange ~~by reference therein~~Act. ☐

~~SIGNATURES~~Item 5.07 Submission of Matters to a Vote of Security Holders

~~Pursuant~~Ocean toBio-Chem, Inc. (the ~~requirements~~“Company”) ofheld ~~the~~its ~~Securities~~Annual ~~Exchange~~Meeting of ~~Act~~Stockholders ofon ~~1934~~June 3, ~~the Registrant~~2022. ~~has~~The ~~duly~~proposals ~~caused~~submitted ~~this~~by ~~report~~the Board of Directors to bea ~~signed~~vote onof ~~its~~the ~~behalf~~shareholders, byand the ~~undersigned~~results ~~thereunto~~of ~~duly~~the voting ~~authorized~~on each proposal, are noted below.

	OCEAN BIO-CHEM, INC.
Date: May 25, 2022	By:	/s/ Jeffrey S. Barocas
		Jeffrey S. Barocas
		Chief Financial Officer

Proposal No. 1 — Election of Directors.

The following nominees were elected by the shareholders to serve on the Company’s Board of Directors until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified:

Nominees	For		Withhold		Non-Votes
Jeffrey S. Barocas		6,401,777		534,333		1,555,592
Diana M. Conard		6,759,163		176,947		1,555,592
Gregor M. Dornau		6,403,757		532,353		1,555,592
Peter G. Dornau		6,409,729		526,381		1,555,592
William W. Dudman		6,403,277		532,833		1,555,592
James M. Kolisch		6,219,286		716,824		1,555,592
Kimberly A. Krause		6,759,380		176,730		1,555,592
John B. Turner		6,748,377		187,733		1,555,592

Proposal No. 2 — Ratification of the Appointment of Independent Registered Public Accounting Firm.

The shareholders ratified the appointment of Accell Audit & Compliance, PA as the Company's independent registered public accounting firm for 2022. The voting results were as follows:

For		Against		Abstain		Non-Votes

	8,488,168		2,800		734		-

Proposal No. 3 — Advisory Vote on the Compensation of our Named Executive Officers;

The shareholders approved, on an advisory basis, the compensation of our named executive officers. The voting results were as follows.

For		Against		Abstain		Non-Votes

	6,886,668		32,432		17,010		1,555,592

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	OCEAN BIO-CHEM, INC.

Date: June 03, 2022	By:	/s/ Jeffrey S. Barocas
		Jeffrey S. Barocas
		Chief Financial Officer

Filing Compare · OCEAN BIO CHEM INC